menu
    • menu
    [{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"BTG International Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Beta-radiation||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ BTG International Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ BTG International Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Biocompatibles UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Beta-radiation||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boston Scientific \/ Biocompatibles UK","highestDevelopmentStatusID":"8","companyTruncated":"Boston Scientific \/ Biocompatibles UK"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Sirtex Medical \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Genentech","sponsor":"Aiwu Ruth He","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Beta-radiation||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Aiwu Ruth He","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Aiwu Ruth He"}]

    Find Clinical Drug Pipeline Developments & Deals for Yttrium Radioisotopes

    Menu

    Yttrium Radioisotopes

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sirtex Medical

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres® Y-90 resin microsp...

                            Details : SIR-Spheres Y-90 resin microspheres is the first therapeutic radiopharmaceutical approved by the NMPA based on clinical trial data, for the treatment of patients with colorectal cancer liver metastases.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 09, 2022

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Boston Scientific

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Boston Scientific

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Biocompatibles UK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TheraSphere With Durvalumab and Tremelimumab for HCC

                            Details : Yttrium-90 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 01, 2021

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Biocompatibles UK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genentech

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Genentech

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Aiwu Ruth He

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (H...

                            Details : Yttrium-90 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 09, 2020

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Aiwu Ruth He

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MD Anderson Cancer Center

                            Country arrow
                            CTAD25
                            Not Confirmed

                            MD Anderson Cancer Center

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BTG International Inc | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

                            Details : Yttrium-90 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 29, 2013

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BTG International Inc | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth